Junshi Biosciences’ Toripalimab Receives EC Orphan Drug Designation for NPC
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that its PD-1 inhibitor Toripalimab (trade name:...
Company
Yifeng Pharmacy Chain to Establish New Company with Tangshan Deshuntang
China-based Yifeng Pharmacy Chain Co., Ltd (SHA: 603939) announced that its subsidiary, Shijiazhuang Xinxing Pharmacy...
Ji Xing Pharmaceuticals Enrolls First Patient in OC-01 Phase III Study for Dry Eye
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that the first patient has been...
Gan & Lee Pharmaceuticals Doses First Patient in GZR18 Phase II Study for Diabetes and Obesity
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...
Fosun Pharmaceutical to Raise USD 662M via Share Issue for Drug Development and API Base
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced plans to issue...
Tris Pharma and Pediatrix’s Methylphenidate Tablet, Ipsen’s Triptorelin Injection Awarded Priority Review by CDE
The Center for Drug Evaluation (CDE) website shows that US-based Tris Pharma and Pediatrix Therapeutics’...
Roche Posts 5% H1 Sales Growth, Led by New Drugs and Immunodiagnostics
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) reported a 5% year-on-year (YOY) increase in...
InnoCare’s Tafasitamab Receives First Prescription in China’s Bo’Ao Lecheng Pilot Zone
China-based InnoCare (HKG: 9969) announced that the first prescription for its pipeline candidate tafasitamab (trade...
Harbin Gloria Partners with Genolmmune on PD-1 and Neoantigen Therapy for NSCLC
China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has partnered with Genolmmune Therapeutics Biotechnology Co.,...
MAXVAX Biotech Raises RMB500M in Series B to Advance Vaccine Pipelines
MAXVAX Biotechnology LLC, a Chengdu-based vaccine and novel adjuvant developer, reportedly raised RMB500 million ($73.9...
Livzon’s V-01 and V-01D-351 Vaccines Show Strong Safety, Immunity as COVID Boosters
China-based Livzon Pharmaceutical Group (HKG: 1513) released clinical data for its recombinant novel coronavirus fusion...
InxMed Receives $10M Debt Financing from SPD Silicon Valley Bank to Advance FAK Inhibitor IN10018
China-based biotech firm InxMed (Nanjing) Co., Ltd announced it has received $10 million in debt...
Frontera Therapeutics Raises $160M in Series B to Advance Gene Therapy FT-001
Sino-US gene therapy specialist Frontera Therapeutics has closed a $160 million Series B funding round,...
DAC Biotech’s DXC005 ADC Doses First Patient in Beijing Cancer Hospital Trial
China-based Hangzhou DAC Biotech Co., Ltd announced the first patient enrollment and dosing of its...
J&J Q2 Sales Rise 8% but Profits Plunge 23% Amid China COVID Lockdowns
US giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q2 2022 financials, showing 8.0% year-on-year...
Novartis Q2 Results Show 5% Growth, Led by Entresto and Cosentyx
Swiss pharma giant Novartis (NYSE: NVS) reported a 5% year-on-year (YOY) revenue increase in constant...
Aidea Pharmaceutical Acquires 19.96% ND Pharm Stake to Boost Urokinase Business
China’s Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has acquired a 19.96% stake in ND...
MicroPort CardioFlow Completes First Clinical Use of Dry Valve Transcatheter Mitral Valve System
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...
WuXi Biologics to Build $1.4B CRDMO Hub in Singapore, Creating 1,500 Jobs
China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...
Antengene and Celularity Partner on Bispecific Antibody and NK Cell Therapy Combo
China-based Antengene Corporation Ltd (HKG: 6996) announced a preclinical partnership with U.S. firm Celularity Inc....